Actively Recruiting
Neuromuscular Fatigue During Exercise in COPD-HF Overlap
Led by University Hospital, Grenoble · Updated on 2024-06-24
40
Participants Needed
1
Research Sites
144 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Rationale. Chronic obstructive pulmonary disease (COPD) and heart failure (HF) coexist in approximately one third of patients presenting with one of these conditions. From a clinical standpoint, impaired tissue oxygen (O2) delivery stands as a common pathological mechanism of these cardiorespiratory diseases. Recent evidence suggest that muscle and cerebral blood flow and oxygenation are further impaired during exercise in patients with COPD-HF overlap compared to isolated diseases. However, it remains unknown whether impaired O2 delivery is associated with exaggerated manifestations of peripheral and central fatigue in COPD-HF overlap. In addition, improving cardiopulmonary interactions through non invasive positive pressure ventilation or through the addition of a hyperoxic gas mixture during exercise have been associated with enhanced cerebral and muscle O2 delivery and oxygenation in patients with COPD or HF. It is, therefore, conceivable that improved O2 delivery to these structures have beneficial influence on exercise capacity in patients with COPD-HF overlap due to less peripheral and central fatigue. Aims. To investigate the influence of impaired O2 delivery during exercise, and its alleviation with different interventions (non invasive positive pressure ventilation or hyperoxia), on neuromuscular fatigue in patients with COPD-HF.
CONDITIONS
Official Title
Neuromuscular Fatigue During Exercise in COPD-HF Overlap
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosis of COPD with mild-to-severe airflow obstruction (FEV1/FVC ratio <0.70; post-bronchodilator FEV1 > 30% predicted)
- Heart failure with reduced left ventricular ejection fraction (<50%) for COPD-HF patients
- New York Heart Association Functional Classification I to III for COPD-HF patients
- Clinical stability for both COPD and/or heart failure with no exacerbations requiring medication changes in the past 3 months
- Patient benefits from health care coverage
- Patient able to provide written informed consent
You will not qualify if you...
- Unable to perform cycle ergometry exercise test
- Having medical devices incompatible with magnetic stimulation
- Contraindication to exercise testing
- Refusal to sign written informed consent
- Not benefiting from health care coverage
- Exceeding annual authorized compensation limits from clinical trial participation
- Deprived of freedom by judicial or administrative decision
- Under legal protection measures (safeguard of justice, guardianship, curatorship) preventing clinical trial inclusion
- Pregnant or nursing women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHU Grenoble Alpes - Hopital Sud (Laboratoire HP2)
Échirolles, Auvergne-Rhône-Alpes, France, 38130
Actively Recruiting
Research Team
S
Stéphane Doutreleau, MD, PhD
CONTACT
M
Mathieu Marillier, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here